Longitudinal study of inflammation and relapse in schizophrenia

Brian J. Miller; Henrique Lemos; Nina R. Schooler; Donald C. Goff; Alexander Kopelowicz; John Lauriello; Theo Manschreck; Alan Mendelowitz; Del D. Miller; Joanne B. Severe; Daniel R. Wilson; Donna Ames; Juan Bustillo; John M. Kane; Mark H. Rapaport; Peter F. Buckley

doi:10.1016/j.schres.2022.12.028

Back

Longitudinal study of inflammation and relapse in schizophrenia

Journal article

Open access

Peer reviewed

Longitudinal study of inflammation and relapse in schizophrenia

Brian J. Miller, Henrique Lemos, Nina R. Schooler, Donald C. Goff, Alexander Kopelowicz, John Lauriello, Theo Manschreck, Alan Mendelowitz, Del D. Miller, Joanne B. Severe, …

Schizophrenia research, Vol.252, pp.88-95

02/2023

DOI: 10.1016/j.schres.2022.12.028

PMCID: PMC9974903

PMID: 36634452

Files and links (1)

url

https://pmc.ncbi.nlm.nih.gov/articles/PMC9974903/pdf/nihms-1864333.pdfView

Open Access

Abstract

Introduction: The clinical course of schizophrenia is often characterized by recurrent relapses. Blood inflammatory markers are altered in acute psychosis, and may be state markers for illness relapse in schizophrenia. Few studies have investigated longitudinal, intra-individual changes in inflammatory markers as a predictor of relapse. In the present study, we explored this association in a relapse prevention trial in patients with schizophrenia. Methods: We analyzed blood inflammatory markers in 200 subjects, with a mean 11 samples per subject, during the 30 month Preventing Relapse in schizophrenia: Oral Antipsychotics Compared to Injectable: eValuating Efficacy (PROACTIVE) trial. Associations between longitudinal changes in inflammatory markers and relapse were analyzed using a within-subjects design. Results: 70 (35 %) of subjects relapsed during the study period. There were no significant differences in mean inflammatory marker levels based on relapse status (yes/no). Baseline levels of inflammatory markers did not predict incident relapse. Among subjects who relapsed, there was a significant decrease in mean blood IL-6 (n = 38, p = 0.019) and IFN-γ (n = 44, p = 0.012) levels from the visit before the relapse to the visit after relapse. Conclusion: Although there was some evidence for inflammation as a potential state marker for acute psychosis, we did not find significant evidence for its utility as a relapse-predictive marker.

Details

Title: Subtitle: Longitudinal study of inflammation and relapse in schizophrenia
Creators: Brian J. Miller
Henrique Lemos
Nina R. Schooler
Donald C. Goff
Alexander Kopelowicz
John Lauriello
Theo Manschreck
Alan Mendelowitz
Del D. Miller
Joanne B. Severe
Daniel R. Wilson
Donna Ames
Juan Bustillo
John M. Kane
Mark H. Rapaport
Peter F. Buckley
Resource Type: Journal article
Publication Details: Schizophrenia research, Vol.252, pp.88-95
DOI: 10.1016/j.schres.2022.12.028
PMID: 36634452
PMCID: PMC9974903
NLM abbreviation: Schizophr Res
ISSN: 0920-9964
eISSN: 1573-2509
Grant note: DOI: 10.13039/100007123, name: Stanley Medical Research Institute; DOI: 10.13039/100012127, name: Augusta University; DOI: 10.13039/100000025, name: National Institute of Mental Health, award: K23MH098014
Language: English
Date published: 02/2023
Academic Unit: Psychiatry
Record Identifier: 9984358158702771

Metrics

22 Record Views

8 Times Cited - Web of Science

See more details